乳腺癌中的ADAR1介导RNA编辑:分子机制和治疗含义
Si-Yu Chen1, Si-Ying Chen1, Shu Yang1
1Department of Biochemistry and Molecular Biology, Molecular Medicine and Cancer Research Center, College of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Medical oncology (Northwood, London, England)
|August 9, 2025
概括
作用于RNA1 (ADAR1) 的腺氨酸脱氨酶在乳腺癌进展和治疗耐药性方面发挥着关键作用. 向ADAR1为开发新型乳腺癌治疗提供了一个有前途的战略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 乳腺癌 (BC) 仍然是全球癌症相关死亡的主要原因.
- 目前的治疗方法面临着由于耐药性,转移和入侵的挑战.
- 迫切需要新的生物标志物和治疗策略来改善患者的治疗结果.
研究的目的:
- 审查作用于RNA1 (ADAR1) 的腺氨酸脱氨酶在乳腺癌进展中的多方面的作用.
- 探索ADAR1的上游调节器和对关键癌症途径的下游影响.
- 确定挑战,并为ADAR1向乳腺癌治疗提出创新策略.
主要方法:
- 对乳腺癌中ADAR1的当前文献进行系统审查.
- 分析ADAR1在基因表达,RNA稳定性,拼接和翻译方面的功能.
- 检查ADAR1在瘤发育,增殖和治疗耐药性的参与.
主要成果:
- 编辑ADAR1与调节乳腺癌生长和抵抗的关键途径有关.
- ADAR1影响RNA的稳定性,拼接和翻译,影响癌症的进展.
- 目前对ADAR1在乳腺癌中的调控网络的理解得到了巩固.
结论:
- ADAR1是乳腺癌发病和治疗耐药性的重要因素.
- 对ADAR1介导机制的进一步研究对于克服治疗挑战至关重要.
- ADAR1 抑制剂代表了在乳腺癌治疗中推进精准医学的潜在途径.
相关概念视频
RNA Editing
9.2K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.2K
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
RNA Interference
26.4K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.4K
RNA Splicing
57.0K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.0K


